A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 479
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HAQ-DI
Long Form : Health Assessment Questionnaire-Disability Index
No. Year Title Co-occurring Abbreviation
2022 A quantitative assessment of the risk of falls in rheumatoid arthritis patients and determination of the risk factors. CDAI, DAS28, FES-I, RA, SDAI
2022 Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis. AS, BASDAI, ED, HCRU, PROs
2022 Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs. ACR, ADA, BSA, DAPSA28, DAS28, ESR, mMDA, nbDMARD, OR, PGA, PsA, PtGA
2022 Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout. HRQoL, SDS, SU, ULT
2022 Clinical observations of osteoporosis in Japanese patients with rheumatoid arthritis. BMI, DAS28, RA
2022 Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. ACR, AEs, CIs, JAKi, MTX, RA, RCTs, RD, TEAEs
2022 Depression in psoriatic arthritis: Related to socio-demographics, comorbid loads or disease activity? DAPSA, HADS, PsA, taub
2022 Driving Impairment and Healthcare Provider Counseling in Rheumatoid Arthritis and Osteoarthritis Patients: A Cross-Sectional Survey. OA, RA
2022 Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. CfB, PASS, PRO, PsA, PsAID, SE, VAS
10  2022 Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. DSS, FACIT-F, MCS, PASDAS, PCS, PF, PROs, PsA, SF-36, WLQ
11  2022 Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis. DAS28-ESR, GLM, MTX, RA
12  2022 Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis. bDMARDs, MD, MTX, PASI, PsA, QoL, RCTs
13  2022 Effects of Locomotion Training on the Physical Functions and Quality of Life in Patients with Rheumatoid Arthritis: A Pilot Clinical Trial. RA, TUG
14  2022 Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. AS, axPsA, BASDAI, CRP, DAPSA, IGA, IL, MRI, PsA, SI, SPARCC
15  2022 Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. BMI, CDAI, RA
16  2022 Factors Associated With the Quality of the Patient-Doctor Relationship: A Cross-Sectional Study of Ambulatory Mexican Patients With Rheumatic Diseases. CI, OR, PDR, SF-36
17  2022 Functional disability and health-related quality of life among systemic sclerosis patients in Bangladesh. ACR/EULAR, HRQoL, MCS, PCS, SF-36, SSc
18  2022 Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. ACR, FIL200, RA
19  2022 Health care utilization and costs associated with functional status in patients with psoriatic arthritis. ED, HCRU, PsA
20  2022 Home-based rehabilitation improves functional capacity and quality of life in women with systemic sclerosis: A preliminary study. ADLs, CHFS, HGS, QoL, SF-36, SSc, TGlittre, TOHR
21  2022 Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. FACIT, FVC, HRQoL, PRO, SGRQ, SHAQ VAS, SSc
22  2022 Impact of Physician-Defined Flares on Quality of Life and Work Impairment: An International Survey of 2,238 Psoriatic Arthritis Patients. EQ-5D-5L, PROs, PsA, PsAID-12, QoL, WPAI
23  2022 Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. ABA, bDMARD-IR, csDMARDs, EQ-5D-5L, FACIT-F, LSM, MCID, PCS, PROs, PtGA, RA, UPA, VAS, WPAI
24  2022 Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept. CRP, DAS28, MRI, RA
25  2022 Presence of Autoantibodies in Males and Females With Rheumatoid Arthritis: A Systematic Review and Metaanalysis. ACPA, DAS28, OR, RA, RF
26  2022 Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study. PROs, PsA, PsAID12, PsARC, REF
27  2022 The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2. EQ-5D, FACIT-Fatigue, MCID, PBO, PROs, PsA, PtGA, RZB, WPAI
28  2022 The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. DAS28-ESR, EQ-5D-3L, HRQoL, PROs, RA, SD, WPAI
29  2022 The frequency of fibromyalgia in familial Mediterranean fever and its impact on the quality of life. CRP, ESR, FIQ, FMF, FMS, ISSF, QoL, SF-36
30  2022 The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. bDMARD-IR, cs, FACIT-Fatigue, FIL200, IR, MTX, PBO, PCS/MCS, PROs, PtGA, WPAI-RA
31  2022 The Impact of Metabolic Syndrome on Quality of Life Among Individuals With Knee Osteoarthritis Living in Egypt. HRQoL, IL, K/L, MetS, OA, WOMAC
32  2022 The Importance of Foot Function Assessment Using the Foot Function Index-Revised Short Form (FFI-RS) Questionnaire in the Comprehensive Treatment of Patients with Rheumatoid Arthritis. DAS28, FFI-RS, RA, VAS
33  2022 The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan. AEs, ESR, IFX, MENA, RA, SAEs
34  2022 Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. FACIT-F, MDA, PASDAS
35  2022 Tofacitinib monotherapy and erectile dysfunction in rheumatoid arthritis: a pilot observational study. DAS28, ED, IIEF-5, RA
36  2022 Women With Psoriatic Arthritis Experience Higher Disease Burden Than Men: Findings From a Real-World Survey in the United States and Europe. EQ-5D, PsA, QoL, WPAI, WPAI
37  2022 Yunpi Qufeng Chushi Formula for Pre-Rheumatoid Arthritis: Study Protocol for a Multiple-Center, Double-Blind, Placebo-Controlled Randomized Controlled Trial. CDAI, FACIT-F, RA, SDAI, TCM, YQCF
38  2022 [The characteristics and associated factors of functional limitation in patients with rheumatoid arthritis]. CDAI, ESR, RA, VAS
39  2021 A comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity. CRP, DAS28, ESR, IL-1beta, MDA, RA, TNF-alpha
40  2021 Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high with worsening of patient-related outcomes. RA
41  2021 Angiotensin-Receptor Blockade Improves Inflammation and Endothelial Dysfunction in Ankylosing Spondylitis: ARB-AS Study. ARBs, AS, ASDAS, BASDAI, BASFI, CRP, CV, EPCs, ESR, FMD, ICAM-1, IL-1, QoL, SCORE, TBARS, TNF-alpha, VCAM-1
42  2021 Association between core stability and physical function, functional performance in patients with systemic sclerosis. 6MWT, SSc, STS
43  2021 Cardiovascular risk factors are negatively associated with rheumatoid arthritis disease outcomes. CDAI, CI, CVD, DAS28-ESR, RA
44  2021 Clinical Manifestations and Outcomes in Disease-Modifying Antirheumatic Drug-Naive Adult Patients with Chronic Chikungunya Arthritis. CDAI, CHIKV, DMARDs
45  2021 Clinical performance of rheumatoid arthritis impact of disease score: a real-life evidence from the multicenter nationwide registry BioStaR. CDAI, PGA, PhyGA, RA, RAID, SDAI
46  2021 Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea. ACR, bDMARDs, csDMARD, QALYs, RA
47  2021 Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. ACR20, AEs, bDMARDs, CrI, csDMARDs, DAS28, DMARD, JAK, ORs, RA, RCTs, WMDs
48  2021 Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. ACR, CDAI, CI, RA, s.c, SDAI
49  2021 Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China. ABN, cDMARDs, GDP, ICER, LDA, MTX, QALY, RA
50  2021 Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. ACPA, RA
51  2021 Diagnosis of Hypophosphatasia in Adults Presenting With Metatarsal Stress Fracture: Proof-of-Concept for a Case-Finding Strategy. ALP, BPI, HPP, MSF, SF36v2
52  2021 Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. CDAI, CRP, MTX
53  2021 Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients. CDAI, IV TCZ, PDUS, RA, US34-PDUS
54  2021 Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. PGA, PtGA, RSS, SSc
55  2021 Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. DAS28, HR-pQCT, MCP, RA
56  2021 Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study. ACPA, MTX, RA
57  2021 Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. ACR, DSS, LEI, MTX, PASI, PsA
58  2021 Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. bDMARD, csDMARD, IR, LDA, NRI, SDAI
59  2021 Engineered glove to evaluate hand disability in rheumatoid arthritis: A pilot-study. HAQ, HCs, HDI, HGS, HTS, ITI, MR, RA, TD
60  2021 Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. ACR20, RA, RCTs
61  2021 Evaluating the strength of spinal and proximal girdle muscles in patients with axial spondyloarthritis: Correlation with activity, disability, and functionality. axSpA, BASDAI, max, TF, TE
62  2021 Evaluation of levels of oxidative stress as a potential biomarker in patients with rheumatoid arthritis. RA, ROS
63  2021 Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study. HADS, OR, PtGA, RA
64  2021 Functional Disability among Systemic Sclerosis Patients: Relation to Disease Characteristics and Quality of Life Parameters. HRQoL, SF-36
65  2021 Functional exercise capacity in rheumatoid arthritis unrelated to lung injury: A comparison of women with and without rheumatoid disease. ADL, CHFS, HGS, QS, RA, RA-PD
66  2021 Hip involvement in children with enthesitis related arthritis (ERA) is associated with poor outcomes in adulthood. ERA, SpA
67  2021 Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. BMI, FACIT-F, PASI, PCS, PsA, SF-36v2
68  2021 Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine. EQ-5D-5L, EQ-VAS, HAQ-VAS, HRQoL, RA
69  2021 Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. FACIT-F, MCID, non-bDMARD-IR, PROs, PsA, PtGA, SF-36
70  2021 Influence of dietary habits on depression among patients with rheumatoid arthritis: A cross-sectional study using KURAMA cohort database. HADS, RA
71  2021 Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? CS, CSI, DAPSA, PsA, RA
72  2021 Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. AHSCT, EFS, FVC, GRCS, mRSS, OS, SSc
73  2021 Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. ADRs, DAS
74  2021 Markers of disease severity and positive family history are associated to significant risk perception in rheumatoid arthritis, while compliance with therapy is not: a cross-sectional study in 415 Mexican outpatients. RA, RAPID3, RP, RPQ, SF-36, VAS
75  2021 Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaire-Disability Index. ICCs, MDHAQ, PsA
76  2021 Muscle wasting, a neglected complication associated with physical dysfunction in elderly patients with rheumatoid arthritis: a cross-sectional observational study. ASMI, DAS28-CRP, mTSS, RA
77  2021 Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. MSK
78  2021 OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. GRAPPA, PsA, SLRs, SOMP, TAG
79  2021 Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. DMARDs, ET, MCIDs, PGA, RA, SGAP, WPAI
80  2021 Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. MCID, PASS, PROMs, RCTs, SLAQ, SLE, VAS
81  2021 Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study. FACIT-F, MTX, PROs, RA
82  2021 Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. CDAI, DAS28-ESR, ESR, FACIT-F, MCID, PRO, RA, RCI, SJC, TJC, WPAI
83  2021 Predictors of functional capacity as measured by the Glittre activities of daily living test in women with rheumatoid arthritis. CT, GA-T, PFTs, RA
84  2021 Role and effectiveness of complex and supervised rehabilitation on overall and hand function in systemic sclerosis patients-one-year follow-up study. CHFS, DAHS, SHAQ, SSc
85  2021 Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. FMT, PsA
86  2021 Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis. ACCP, ELISA, RA, RF, SJ-28, TJ-28, TNF-alpha
87  2021 Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. ICC, OMERACT, PsA
88  2021 The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. ACR, DAS-28, MET, RA
89  2021 The association between disease duration and mood disorders in rheumatoid arthritis patients. GS, RA, SAS, SDS
90  2021 The association between incident vertebral deformities, health-related quality of life and functional impairment: a 10.7-year cohort study. DXA, HRQoL, VDs
91  2021 The Efficacy of a Home-Based, Self-Administered Hand Exercise Program for Patients With Systemic Sclerosis: A Randomized Controlled, Evaluator-Blind, Clinical Trial. BAI, BDI, dcSSc, DHI, HAMIS, lcSSc, SSc
92  2021 The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study). CDAI, csDMARDs, DAS28, EQ-5D-5L, HCQ, MTX, RA, SDAI, SF-6D, SSZ, TNFi
93  2021 The relationship between kinesiophobia and health-related quality of life in patients with rheumatoid arthritis: A controlled cross-sectional study. BDI, BMI, FSS, HRQoL, IPAQ, RA, TSK
94  2021 Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China. bDMARDs, CDAI, csDMARDs, DMARDs, PhGA, PtGA, RA, SDAI, VAS
95  2021 Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). DLQI, PROs, PsA, QoL, RA, ref-ADL, SD
96  2021 Validity and reliability of 6-minute pegboard and ring test in patients with asthma. AQLQ, CI, ICC, MAS
97  2021 Yoga improves mitochondrial health and reduces severity of autoimmune inflammatory arthritis: A randomized controlled trial. mtDNAcn, OS, RA
98  2020 A new laboratory surrogate (Monocyte Chemotactic Protein-1) for Disease Activity Score28: a favourable indicator for remission in rheumatoid arthritis. DAS28-ESR, DAS28-MCP-1, RA, SDAI
99  2020 A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. DUs, SSc, VAS
100  2020 Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study. PAH, SSc